Form 4 for MBIO MUSTANG BIO, INC.
Accepted 2023-07-07 00:00:00 ET · period of report 2023-04-24 · accession 0001104659-23-079110 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-07 | 2023-04-24 | MBIO | Litchman Manuel MD | Pres, CEO, Dir | A - Grant | $0.00 | +5,000 | 111.1K | +5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK, PAR VALUE $0.0001 | 2023-04-24 | A | A | 5,000 | $0.00 | 111,079 | D | — | — | (F1) Represents an award of 5,000 restricted stock units that will vest in four annual installments after the grant date, vesting in full on April 24, 2027. (F2) Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. (F3) Includes restricted share units, which vest over various time periods. |